Damora Therapeutics, Inc.

DMRA

Damora Therapeutics, Inc.

DMRA

Insider Sentiment (TTM):

Last Purchase:-Last Sale:2026-01-02Shares Purchased (TTM):0Shares Sold (TTM):1,090

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:53,563,262Shares Outstanding:34,299,182Institutional Ownership Pct.:156.16%

Earnings Market Reaction:

Filing Date:2026-08-10Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Related Party	-	0	0	-	-	-	-	-	-	-	-	-
Series B Non Voting Convertible Preferred Stock	-	0	0	-	-	-	0	-	-	-	-	-
Series C Non Voting Convertible Preferred Stock	-	0	0	-	-	-	0	-	-	-	-	-
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	541	533	258	8	10	12	14	20	23	21	21	23
Marketable Securities Current	-	-	-	-	-	-	-	-	-	6	12	21
Prepaid Expense And Other Assets Current	3	3	3	2	3	3	3	2	2	3	4	3
Assets Current	544	535	260	10	13	15	17	21	25	31	37	47
Operating Lease Right Of Use Asset	-	-	0	0	0	0	0	0	0	0	0	0
Property Plant And Equipment Net	-	-	0	0	0	0	0	0	0	0	0	0
Other Assets Noncurrent	0	0	0	1	1	0	0	2	2	2	1	2
Assets	544	535	261	11	14	15	17	23	27	32	38	50
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	3	1	0	1	1	0	0	1	1	2	2	4
Accrued Liabilities And Other Liabilities	9	6	2	2	2	1	1	2	3	3	4	8
Option Contract Indexed To Equity Settlement Share…	10	5	-	-	-	-	-	-	-	-	-	-
Liabilities Current	28	24	20	3	3	2	1	2	4	4	6	13
Operating Lease Liability Noncurrent	-	-	0	0	0	0	0	-	-	-	0	0
Other Liabilities Noncurrent	0	0	0	0	0	0	0	-	-	-	-	-
Liabilities	28	24	20	3	3	2	1	2	4	4	6	13
Temporary Equity Carrying Amount Attributable To P…	0	1	1	1	1	1	1	-	-	-	-	-
Stockholders Equity
Common Stock Value	0	0	-	-	-	-	-	-	-	-	-	-
Additional Paid In Capital	932	894	311	292	292	292	292	291	290	289	288	287
Retained Earnings Accumulated Deficit	-546	-515	-487	-287	-283	-280	-278	-271	-267	-262	-256	-250
Accumulated Other Comprehensive Income Loss Net Of…	1	1	1	1	1	0	0	1	0	0	0	0
Stockholders Equity	516	512	240	8	11	14	16	21	24	28	32	37
Liabilities And Stockholders Equity	544	535	261	11	14	15	17	23	27	32	38	50
Preferred Stock Par Or Stated Value Per Share	-	-	-	-	-	-	-	0	0	0	0	0
Temporary Equity Par Or Stated Value Per Share	0	0	0	0	0	0	0	-	-	-	0	-
Temporary Equity Shares Authorized	10	10	10	10	10	10	10	-	-	-	10	-
Temporary Equity Shares Issued	0	0	0	0	0	0	0	-	-	-	0	-
Temporary Equity Shares Outstanding	0	0	0	0	0	0	0	-	-	-	0	-
Preferred Stock Shares Authorized	10	10	10	-	-	-	-	10	10	10	10	10
Preferred Stock Shares Issued	-	-	-	-	-	-	-	0	0	0	0	0
Preferred Stock Shares Outstanding	-	-	-	-	-	-	-	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	500	500	500	300	300	300	500	300	300	300	300	300
Common Stock Shares Issued	62	60	2	1	1	1	1	1	1	1	1	1
Shares Outstanding	62	60	2	1	1	1	1	1	1	1	1	1

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-9.01%	29.84%	25.55%	-	-	-	-	-	-	-	-	-
2025	8.10%	20.42%	32.04%	-6.47%	29.71%	147.94%	205.50%	486.60%	342.61%	34.48%	25.83%	9.43%
2024	-10.23%	-29.10%	-20.76%	-12.37%	-8.28%	-47.00%	-16.74%	-30.37%	-24.01%	-45.15%	-35.11%	-22.22%
2023	-	-	-	-	-	-	-3.85%	15.38%	7.37%	-10.36%	-19.00%	-27.61%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	19.73	22.48	12.98	3.73	4.96	9.62	14.07	8.68	6.79	7.07	6.31	3.75
Quick Ratio	19.62	22.38	12.84	2.90	3.88	7.70	11.84	8.06	6.16	6.29	5.69	3.52
Working Capital	516.04M	511.60M	240.36M	7.16M	10.40M	13.37M	15.64M	18.74M	21.46M	26.22M	30.94M	34.50M
Leverage & Debt
Debt to Equity	0.05	0.05	0.08	0.34	0.25	0.12	0.08	0.12	0.16	0.15	0.18	0.34
Interest Coverage TTM	-33.12	-57.43	-180.70	-41.31	-34.06	-28.92	-26.37	-22.83	-20.71	-21.27	-23.63	-28.63
Debt Ratio	0.05	0.04	0.08	0.25	0.20	0.11	0.08	0.10	0.14	0.13	0.15	0.25
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Per Share Metrics
Diluted EPS TTM	-4.30	-6.85	-153.95	-11.94	-12.55	-13.99	-18.53	-18.49	-23.44	-28.43	-36.08	-42.38
Free Cash Flow Per Share TTM	-0.43	-0.73	-4.93	-7.38	-8.18	-11.44	-16.09	-21.98	-27.63	-31.09	-34.73	-34.06
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Growth Metrics
Net Income Growth (1Y)	1,483.86%	1,171.09%	878.77%	-25.17%	-34.74%	-40.01%	-44.10%	-53.91%	-50.66%	-46.55%	-37.77%	-24.64%
EPS Growth (1Y)	-65.73%	-51.01%	730.95%	-35.44%	-46.48%	-50.79%	-48.65%	-56.36%	-52.01%	-49.39%	-40.49%	-29.12%
Valuation Metrics
P/E TTM	-6.05	-3.78	-0.15	-0.31	-0.27	-0.22	-0.25	-0.66	-0.51	-0.69	-0.50	-0.42
P/B TTM	3.08	1.74	0.13	0.62	0.41	0.30	0.34	0.66	0.54	0.75	0.59	0.52
Market Cap	1.59B	888.35M	31.36M	4.94M	4.51M	4.10M	5.38M	13.91M	12.85M	21.15M	19.13M	19.52M
Enterprise Value	1.05B	355.45M	-196.51M	-2.67M	-5.70M	-7.84M	-8.79M	-5.77M	-10.01M	56.93K	-2.33M	-3.56M
Calculated Values
Free Cash Flow TTM	-26.36M	-24.89M	-6.73M	-9.79M	-10.82M	-15.13M	-18.62M	-25.16M	-29.96M	-33.71M	-36.91M	-36.93M
Net Debt	-540.52M	-532.90M	-227.87M	-7.61M	-10.21M	-11.94M	-14.18M	-19.68M	-22.86M	-21.09M	-21.47M	-23.08M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-01-02Sale

Owner: Schambye, Hans T.

Title: Chief Executive Officer

Shares: 700

Price/Share: $21.38

Value: $14,966.00

Shares Owned: 4,682

Relationship: Director,Officer

Ownership: Direct

2026-01-02Sale

Owner: Winslow, Garrett

Title: General Counsel

Shares: 255

Price/Share: $21.38

Value: $5,451.90

Shares Owned: 1,854

Relationship: Officer

Ownership: Direct

2026-01-02Sale

Owner: Firmani, Lori

Title: Chief Financial Officer

Shares: 135

Price/Share: $21.41

Value: $2,890.35

Shares Owned: 931

Relationship: Officer

Ownership: Direct

2025-07-03Sale

Owner: Winslow, Garrett

Title: General Counsel

Shares: 260

Price/Share: $3.39

Value: $881.40

Shares Owned: 1,429

Relationship: Officer

Ownership: Direct

2025-07-03Sale

Owner: Schambye, Hans T.

Title: Chief Executive Officer

Shares: 735

Price/Share: $3.38

Value: $2,484.30

Shares Owned: 4,022

Relationship: Director,Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-01-02	Schambye, Hans T.	Director,Officer	Chief Executive Officer	Direct	Sale	700	21.38	$14,966.00	4,682	4
2026-01-02	Winslow, Garrett	Officer	General Counsel	Direct	Sale	255	21.38	$5,451.90	1,854	4
2026-01-02	Firmani, Lori	Officer	Chief Financial Officer	Direct	Sale	135	21.41	$2,890.35	931	4
2025-07-03	Winslow, Garrett	Officer	General Counsel	Direct	Sale	260	3.39	$881.40	1,429	4
2025-07-03	Schambye, Hans T.	Director,Officer	Chief Executive Officer	Direct	Sale	735	3.38	$2,484.30	4,022	4
2025-07-03	Firmani, Lori	Officer	Interim CFO	Direct	Sale	147	3.39	$498.33	692	4
2025-01-03	Firmani, Lori	Officer	Interim CFO	Direct	Sale	261	5.63	$1,469.43	465	4
2025-01-03	Schambye, Hans T.	Director,Officer	Chief Executive Officer	Direct	Sale	1,341	5.60	$7,509.60	3,397	4
2025-01-03	Winslow, Garrett	Officer	General Counsel	Direct	Sale	471	5.60	$2,637.60	1,009	4
2023-08-15	Orbimed, Advisors Israel …	TenPercentOwner	-	Indirect	Sale	822,680	0.75	$617,010.00	97,204	4
2023-07-31	Orbimed, Capital Gp Vii L…	TenPercentOwner	-	Indirect	Sale	209,400	3.00	$628,200.00	135,531	4
2023-07-25	Orbimed, Capital Gp Vii L…	TenPercentOwner	-	Indirect	Sale	39,200	2.92	$114,464.00	162,153	4
2023-07-13	Orbimed, Advisors Israel …	TenPercentOwner	-	Indirect	Sale	194,700	2.40	$467,280.00	169,953	4
2023-04-17	Orbimed, Advisors Llc, Or…	TenPercentOwner	-	Indirect	Sale	13,089	1.97	$25,785.33	179,753	4
2023-04-12	Orbimed, Advisors Israel …	TenPercentOwner	-	Indirect	Sale	2,363	1.81	$4,277.03	183,207	4
2023-04-06	Orbimed, Genesis Gp Llc, …	TenPercentOwner	-	Indirect	Sale	9,665	2.00	$19,330.00	186,613	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

156.16%

Inst. Shares: 53,563,262

Shares Outstanding: 34,299,182

2025-12-31

72.45%

Inst. Shares: 987,502

Shares Outstanding: 1,363,005

2025-09-30

11.84%

Inst. Shares: 157,090

Shares Outstanding: 1,327,039

2025-06-30

10.03%

Inst. Shares: 132,660

Shares Outstanding: 1,322,553

2025-03-31

10.78%

Inst. Shares: 142,568

Shares Outstanding: 1,322,011

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	53,563,262	34,299,182	156.16%
2025-12-31	987,502	1,363,005	72.45%
2025-09-30	157,090	1,327,039	11.84%
2025-06-30	132,660	1,322,553	10.03%
2025-03-31	142,568	1,322,011	10.78%
2024-12-31	142,062	1,157,149	12.28%
2024-09-30	128,626	1,144,978	11.23%
2024-06-30	160,224	1,084,622	14.77%
2024-03-31	134,179	1,084,509	12.37%
2023-12-31	137,064	1,062,873	12.90%
2023-09-30	208,413	1,084,191	19.22%
2023-06-30	400,265	1,055,003	37.94%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Damora Therapeutics, Inc. (DMRA) — SEC Financial Statements & Analysis

Damora Therapeutics, Inc. (DMRA) is a pharmaceutical preparations company, incorporated in DE. Damora Therapeutics, Inc. trades on Nasdaq as: DMRA. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Damora Therapeutics, Inc. reported a Debt-to-Equity ratio of 0.05x, a Price-to-Book (P/B) ratio of 3.08x (TTM), at a market cap of $1.59B. Figures below are sourced from SEC EDGAR, as-filed.

Debt To Equity: 0.05x
P/B TTM: 3.08x
Market Cap: $1.59B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Damora Therapeutics, Inc. in?

Damora Therapeutics, Inc. (DMRA) operates in the Pharmaceutical Preparations industry.

What is DMRA's market cap?

Damora Therapeutics, Inc. (DMRA) has a market capitalization of $1.59B as of 2026-06-30.

What exchange does DMRA trade on?

Damora Therapeutics, Inc. (DMRA) trades on the Nasdaq.

Where is Damora Therapeutics, Inc. incorporated?

Damora Therapeutics, Inc. is incorporated in DE.